If you’ve been diagnosed with localized prostate cancer, you may be considering active surveillance or treatment. The Prolaris® + AI Test gives your doctor additional information from your biopsy, including artificial intelligence (AI)-assisted analysis, to help build a more complete understanding of your cancer and guide conversations about your care.
Every prostate cancer is different.
That's why healthcare providers look at multiple pieces of information when discussing your care, including your biopsy results, your overall health and how your tumor behaves.
The Prolaris + AI Test brings those insights together into one report, giving your doctor a more complete picture of your cancer and helping guide conversations about your treatment options.
Clinical information
What your healthcare provider already knows about your diagnosis:
Tumor biology
What your genes reveal about how aggressive your cancer is behaving.1,2
AI-assisted tissue analysis
Additional insight from patterns found in your biopsy tissue to help determine likelihood of higher Gleason score at next biopsy for patients appropriate for active surveillance.3
One report
A fuller picture to help guide your care.
The Prolaris Test has long helped healthcare providers better understand how a patient's prostate cancer is likely to behave by analyzing the activity of genes within the tumor. With the addition of the AI metric, the test can now better help you and your doctors answer questions like:
Using digital images from your existing biopsy tissue, the new AI metric analyzes complex tissue patterns that may provide additional information about your cancer. Combined with your Prolaris genomic score and clinical information, it gives your doctor a more complete picture to help guide decisions about your care.
The AI enhancement works with the biopsy tissue you've already provided, so there's no need for an additional biopsy or procedure.
When you’re considering active surveillance, every piece of information matters.
The Prolaris + AI enhancement helps estimate the likelihood of a higher Gleason score at a future biopsy for eligible patients considering active surveillance.3
Combined with the Prolaris genomic score and your clinical information, it gives your doctor additional insight that may help:
Treatment decisions should always be made together with your healthcare provider.
If treatment is being considered, another important question is how much treatment may be appropriate for your individual cancer.
The Prolaris + AI Test provides personalized information that can help you and your doctor discuss whether a single form of treatment or multiple forms of treatment may be appropriate.
For patients considering radiation therapy, the Prolaris Test can also provide information to help determine whether adding hormone therapy, also called androgen deprivation therapy (ADT), may provide additional benefit, or whether it may be appropriate to avoid ADT and its potential side effects.
The Prolaris + AI Test provides two independent measurements designed specifically to help guide active surveillance decisions.
Clinically validated for active surveillance
Clinically validated in untreated patients, making it uniquely suited to help guide safe active surveillance selection4-6
Guides the ADT conversation
Helps identify which men would benefit from adding hormone therapy (ADT) and who may be appropriate to avoid it.
Every prostate cancer diagnosis is unique, and your care plan should be too. The Prolaris + AI Test is designed for patients who have been newly diagnosed with localized prostate cancer, or are currently on active surveillance. By combining genomic insights with AI-assisted tissue analysis, it provides additional information to help you and your doctor have more informed conversations about active surveillance and treatment.
You may want to ask your doctor about the Prolaris + AI Test if you’re wondering:
Download the Prolaris + AI patient guide
Navigate crucial prostate cancer treatment decisions – with the right answers at the right time.
We are here to help! If you can answer ‘yes’ to any of the following, we can provide educational information to your Urologist.
Are you:
Newly diagnosed with prostate cancer?
Currently on active surveillance?
If you are interested and would like us to reach out to your provider, please fill out their information below
By submitting this form, you agree to be contacted with newsletters, marketing or promotional materials, and other information that may be of interest to you. You may unsubscribe from these communications by following the unsubscribe link or the instructions provided in the communication we send. The information you submit is governed by our Privacy Notice and our website Terms of Use.
You’ll receive a personalized follow up call from a Myriad customer service representative, with the caller ID displaying Myriad Genetics Support Team – Prolaris Test.
Contact Information
If you've recently been diagnosed with localized prostate cancer, ask your urologist whether the Prolaris + AI Test may help inform your care plan
References
This page includes AI generated images. Any similarity or resemblance to persons, living or dead, is purely coincidental.
©2026 Myriad Genetics, Inc. Myriad Genetics, Prolaris and their respective logos, are registered trademarks of Myriad Genetics, Inc. and its subsidiaries in the United States and other jurisdictions.